ストックスクリーナーアプリを入手
0.789
31.00%
0.1867
アフターアワーズ：
.79
0.001
+0.13%
Briacell Therapeutics Corp (BCTX) 最新ニュース
BriaCell begins phase 1/2 trial of Bria-OTS™ for breast cancer | 2024-11-21 | Investing News - Stockhouse Publishing
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study - GlobeNewswire
BriaCell Launches Phase 1/2 Trial of Next-Gen Breast Cancer Immunotherapy | BCTX Stock News - StockTitan
Closing Bell: Briacell Therapeutics Corp Down On Monday (BCT) - Barchart
BriaCell Showcases Robust Anti-Cancer Activity of - GlobeNewswire
BriaCell's Next-Gen Cancer Immunotherapies Show Breakthrough Results in Preclinical Data | BCTX Stock News - StockTitan
BriaCell Overall Survival Data Selected for Spotlight - GlobeNewswire
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13 - StockTitan
BriaCell Therapeutics Faces Uncertain Financial Future - TipRanks
BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2024 - Marketscreener.com
BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns - Seeking Alpha
BriaCell reports survival data from Phase 2 study | 2024-10-22 | Investing News - Stockhouse Publishing
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data - GlobeNewswire
You might want to take a look at BriaCell Therapeutics Corp (BCTX) now - SETE News
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study - GlobeNewswire
BriaCell Therapeutics advances Phase 3 MBC clinical study | 2024-10-15 | Investing News - Stockhouse Publishing
BCTX’s 52-Week Rollercoaster: From $0.46 to $5.97 – What’s Next for Investors? - The InvestChronicle
BriaCell stock gains after trial update (NASDAQ:BCTX) - Seeking Alpha
Extendicare Inc. - Baystreet.ca
BriaCell Therapeutics Corp. - Baystreet.ca
Analyzing BriaCell Therapeutics Corp (BCTX) After Recent Trading Activity - Knox Daily
BriaCell Therapeutics Corp (BCTX)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Deeper Dive: Understanding BriaCell Therapeutics Corp (BCTX) Through its Various Ratios - The Dwinnex
Clean Harbors (CLH-N) QuotePress Release - The Globe and Mail
BriaCell Therapeutics Corp: Navigating a Turbulent Year, Up -82.63% from 52-Week Low - The InvestChronicle
Financial Metrics Check: BriaCell Therapeutics Corp (BCTX)’s Ratios for Trailing Twelve Months - The Dwinnex
It is Poised to be a Bull Market for BriaCell Therapeutics Corp (BCTX) - SETE News
A Guide To The Risks Of Investing In BriaCell Therapeutics Corp (BCTX) - Knox Daily
BMO MSCI ACWI Paris Aligned Climate Equi (ZGRN-T) QuotePress Release - The Globe and Mail
BriaCell Therapeutics’ (BCTX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Briacell stock Buy rating reaffirmed with clinical success in metastatic breast cancer trial - Investing.com
BriaCell Therapeutics Announces Closing of $5 Million Offering - GlobeNewswire
Daily Market Movement: BriaCell Therapeutics Corp (BCTX) Sees a -34.68 Decrease, Closing at 0.81 - The Dwinnex
BriaCell Therapeutics Announces $5 Million Offering - The Manila Times
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor - BioSpace
BriaCell sets price for $5 million share and warrant offering - Investing.com
BriaCell sets price for $5 million share and warrant offering By Investing.com - Investing.com Canada
BriaCell Therapeutics Launches $5 Million Offering - TipRanks
BriaCell stock dips on data for breast cancer drug (NASDAQ:BCTX) - Seeking Alpha
Briacell Reports 100% Resolution Of Brain Metastasis In Breast Cancer Patient With “Eye-Bulging” Tumor - MENAFN.COM
BriaCell Therapeutics Corp. Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor - Marketscreener.com
There is no way BriaCell Therapeutics Corp (BCTX) can keep these numbers up - SETE News
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with 'Eye-Bulging” Tumor - The Manila Times
Understanding the Risks of Investing in BriaCell Therapeutics Corp (BCTX) - Knox Daily
A closer look at BCTX’s price-to-free cash flow ratio - US Post News
BriaCell Therapeutics Corp’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock - Yahoo Finance
BriaCell Therapeutics Corp [BCTX] stock Initiated by H.C. Wainwright analyst, price target now $25 - The DBT News
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Decline in Short Interest - Defense World
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Large Increase in Short Interest - Defense World
A new trading data show BriaCell Therapeutics Corp (BCTX) is showing positive returns. - SETE News
BriaCell Therapeutics Corp’s latest rating changes from various analysts - Knox Daily
Research Analysts Offer Predictions for BriaCell Therapeutics Corp.’s FY2024 Earnings (NASDAQ:BCTX) - Defense World
Brokers Set Expectations for BriaCell Therapeutics Corp.’s FY2024 Earnings (TSE:BCT) - Defense World
HC Wainwright Weighs in on BriaCell Therapeutics Corp.’s FY2029 Earnings (TSE:BCT) - Defense World
BriaCell Therapeutics target cut by H.C. Wainwright - Investing.com
BriaCell Therapeutics (CVE:BCT) Given New C$15.00 Price Target at HC Wainwright - Defense World
Oncolytics Biotech Inc - Baystreet.ca
BioLife Solutions, Inc. (NASDAQ:BLFS) CRO Garrie Richardson Sells 3,070 Shares - Defense World
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):